AMR Drugs and Diagnostics Must Evolve in Tandem

The piece argues that to effectively combat antimicrobial resistance (AMR), drug development and diagnostic innovations must advance together. Simply creating new antibiotics is not enough—without rapid, accurate diagnostics to guide their use, even novel therapies risk being misused and driving new resistance. The article highlights the dwindling pipeline of true antimicrobial innovation, the economic and regulatory hurdles slowing progress, and the importance of alignment between diagnostics and therapeutics. It emphasizes that concerted global investment, incentives, and public–private collaboration are essential to rejuvenate AMR innovation across both treatment and diagnostic domains.